MitraClip offers a percutaneous edge-to-edge repair option for patients with mitral regurgitation, especially those deemed high risk for surgery.
May support MitraClip in high-risk patients; leaves open need for longer-term randomized durability data.
Mitral regurgitation (MR) is a frequent valve disorder. Almost half of all patients with MR are denied treatment on the basis of high surgical risk. Percutaneous mitral valve repair simulating the edge-to-edge technique can be accomplished successfully with the MitraClip® system. The procedure is usually performed under general anesthesia in a catheterization laboratory under fluoroscopic and transesophageal echocardiographic guidance. Initial results from randomized trials (e.g., EVEREST II) suggest that MitraClip is safer and noninferior to surgical valve treatment. Real-world experience in high-risk patients indicates beneficial results of MitraClip implantation in both degenerative and functional MR, with improvement in left ventricular chamber indices at follow-up. Continued development in terms of technique and experience will allow the application of novel percutaneous repair techniques to an expanded cohort of patients with MR.
No takes yet. Share an insight, caveat, or question.
Ussia et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: